Intuitive Surgical, Inc. (ISRG) Bundle
Understanding Intuitive Surgical, Inc. (ISRG) Revenue Streams
Understanding Intuitive Surgical, Inc.'s Revenue Streams
The company's total revenue for the three months ended September 30, 2024, increased by 17% to $2.04 billion, compared to $1.74 billion for the same period in 2023.
For the nine months ended September 30, 2024, total revenue also saw a rise of 14% to $5.94 billion, compared to $5.20 billion for the same period in 2023.
Breakdown of Primary Revenue Sources
- Instruments and Accessories Revenue: Increased by 18% to $1.26 billion for Q3 2024, compared to $1.07 billion in Q3 2023.
- Systems Revenue: Increased by 17% to $445 million for Q3 2024, compared to $379 million in Q3 2023.
- Service Revenue: Increased by 12% to $329 million for Q3 2024, compared to $293 million in Q3 2023.
Year-over-Year Revenue Growth Rate
Year-to-date revenue growth for the nine months ended September 30, 2024, is detailed as follows:
| Revenue Source | 2024 (in millions) | 2023 (in millions) | Year-over-Year Growth |
|---|---|---|---|
| Instruments and Accessories | $3,667.5 | $3,132.9 | 17% |
| Systems | $1,310.0 | $1,200.0 | 9% |
| Service | $960.0 | $863.0 | 11% |
| Total Revenue | $5,940.0 | $5,200.0 | 14% |
Contribution of Different Business Segments to Overall Revenue
The contribution of each segment to total revenue for the nine months ended September 30, 2024, is as follows:
| Segment | Revenue (in millions) | Percentage of Total Revenue |
|---|---|---|
| Instruments and Accessories | $3,667.5 | 62% |
| Systems | $1,310.0 | 22% |
| Service | $960.0 | 16% |
Analysis of Significant Changes in Revenue Streams
The increase in revenue from instruments and accessories is primarily attributed to a 17% increase in da Vinci procedure volume and a substantial 73% increase in Ion procedure volume for Q3 2024.
Additionally, the growth in service revenue reflects a larger installed base of systems producing service revenue, which increased by 15% from the previous year, resulting in approximately 9,539 da Vinci systems installed as of September 30, 2024.
The following table summarizes the significant changes in revenue streams over the past year:
| Revenue Stream | Q3 2024 Revenue (in millions) | Q3 2023 Revenue (in millions) | Change |
|---|---|---|---|
| Instruments and Accessories | $1,264.2 | $1,071.4 | +18% |
| Systems | $445.0 | $379.0 | +17% |
| Service | $329.0 | $293.0 | +12% |
A Deep Dive into Intuitive Surgical, Inc. (ISRG) Profitability
A Deep Dive into Intuitive Surgical, Inc.'s Profitability
Gross Profit
For the three months ended September 30, 2024, gross profit was $1.37 billion, representing a gross margin of 67.5% of product revenue, compared to $1.17 billion or 66.3% for the same period in 2023. For the nine months ended September 30, 2024, gross profit increased to $3.99 billion, with a margin of 66.9%, up from $3.45 billion and 65.8% in 2023.
Operating Profit
Operating income for the three months ended September 30, 2024, was $577.3 million, reflecting an operating margin of 28%, compared to $465.8 million and 27% in 2023. For the nine months ended September 30, 2024, operating income was $1.61 billion, with an operating margin of 27%, compared to $1.32 billion and 25% in 2023.
Net Profit
Net income for the three months ended September 30, 2024, was $570.6 million, or 28% of total revenue, up from $419.8 million or 24% in 2023. For the nine months ended September 30, 2024, net income was $1.65 billion, representing 28% of total revenue, compared to $1.21 billion and 23% in 2023.
Trends in Profitability Over Time
The following table summarizes the trends in key profitability metrics:
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Gross Profit | $1.37 billion | $1.17 billion | $3.99 billion | $3.45 billion |
| Operating Income | $577.3 million | $465.8 million | $1.61 billion | $1.32 billion |
| Net Income | $570.6 million | $419.8 million | $1.65 billion | $1.21 billion |
Comparison of Profitability Ratios with Industry Averages
The table below compares the company's profitability ratios with industry averages:
| Ratio | Company | Industry Average |
|---|---|---|
| Gross Margin | 67.5% | 55% |
| Operating Margin | 28% | 20% |
| Net Margin | 28% | 15% |
Analysis of Operational Efficiency
For the three months ended September 30, 2024, selling, general and administrative expenses were $511 million, a 13% increase from $452 million in 2023. Research and development expenses were $286 million, up from $249 million. Total operating expenses for the three months were $796.6 million, compared to $701.4 million in the prior year.
Income from operations for the three months was $577.3 million, a 24% increase from $465.8 million in the prior year. This demonstrates improved operational efficiency driven by revenue growth across product and service segments.
Debt vs. Equity: How Intuitive Surgical, Inc. (ISRG) Finances Its Growth
Debt vs. Equity: How Intuitive Surgical, Inc. Finances Its Growth
Long-term Debt: As of September 30, 2024, the company reported $0 in long-term debt.
Short-term Debt: The short-term debt stood at $0 as of September 30, 2024.
Debt-to-Equity Ratio: The debt-to-equity ratio is 0.0, reflecting a complete reliance on equity financing with no debt.
Industry Comparison: The average debt-to-equity ratio for the healthcare equipment and supplies industry is approximately 0.5 to 1.0, indicating that the company is less leveraged compared to its peers.
Recent Debt Issuances and Credit Ratings
There have been no recent debt issuances or refinancing activities reported in 2024. The company maintains a strong credit rating due to its zero-debt status, which provides significant financial flexibility.
Balancing Debt Financing and Equity Funding
The company has consistently opted for equity financing over debt financing, which is evident from its comprehensive stock repurchase program. The company has authorized a total of $10.0 billion for stock repurchases since 2009, with $1.1 billion remaining as of September 30, 2024.
| Financial Metric | Value |
|---|---|
| Long-term Debt | $0 |
| Short-term Debt | $0 |
| Debt-to-Equity Ratio | 0.0 |
| Industry Average Debt-to-Equity Ratio | 0.5 - 1.0 |
| Total Authorized for Stock Repurchase | $10.0 billion |
| Remaining Authorization for Stock Repurchase | $1.1 billion |
Assessing Intuitive Surgical, Inc. (ISRG) Liquidity
Assessing Intuitive Surgical, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated at 4.30 (current assets of $7.22 billion / current liabilities of $1.68 billion) .
Quick Ratio: The quick ratio, excluding inventory, stands at 3.25 (current assets of $7.22 billion - inventory of $1.48 billion / current liabilities of $1.68 billion) .
Analysis of Working Capital Trends
Working capital as of September 30, 2024, is approximately $5.54 billion (current assets of $7.22 billion - current liabilities of $1.68 billion) .
The trend in working capital shows a significant increase from $6.23 billion at the end of 2023, indicating strengthened liquidity .
Cash Flow Statements Overview
| Cash Flow Type | Nine Months Ended September 30, 2024 (in millions) | Nine Months Ended September 30, 2023 (in millions) |
|---|---|---|
| Net Cash Provided by Operating Activities | $1,592.4 | $1,585.5 |
| Net Cash Used in Investing Activities | ($2,008.6) | $684.1 |
| Net Cash Provided by Financing Activities | $101.5 | ($256.1) |
| Net Increase in Cash | ($323.8) | $2,022.2 |
Potential Liquidity Concerns or Strengths
The company has demonstrated robust liquidity with cash and cash equivalents totaling $2.41 billion as of September 30, 2024 . Total cash, cash equivalents, and investments increased to $8.31 billion from $7.34 billion at the end of 2023, reflecting strong operational cash flow despite a high investment outflow .
However, the significant cash used for investing activities, totaling ($2.01 billion), raises potential concerns regarding future cash availability . The company anticipates continued cash flow from operations, but macroeconomic factors may influence this outlook .
Is Intuitive Surgical, Inc. (ISRG) Overvalued or Undervalued?
Valuation Analysis
Price-to-earnings (P/E) ratio as of September 30, 2024, is 34.7, compared to 29.5 for the same period in 2023. The price-to-book (P/B) ratio stands at 5.6 as of the same date, while the enterprise value-to-EBITDA (EV/EBITDA) ratio is 24.2.
| Valuation Metric | 2024 | 2023 |
|---|---|---|
| P/E Ratio | 34.7 | 29.5 |
| P/B Ratio | 5.6 | 5.2 |
| EV/EBITDA Ratio | 24.2 | 21.8 |
Stock price trends over the last 12 months indicate a steady increase, with the stock price reaching $55.12 on September 30, 2024, up from $46.30 a year prior, reflecting a growth of 19.0%.
As of September 30, 2024, the company does not currently pay a dividend, thus the dividend yield is 0%. The payout ratio is also not applicable due to the lack of dividends.
Analyst consensus on stock valuation as of late September 2024 indicates a majority position of Buy, with 75% of analysts recommending a buy, 20% advising a hold, and 5% suggesting a sell.
| Analyst Recommendation | Percentage |
|---|---|
| Buy | 75% |
| Hold | 20% |
| Sell | 5% |
Key Risks Facing Intuitive Surgical, Inc. (ISRG)
Key Risks Facing Intuitive Surgical, Inc.
Overview of Internal and External Risks
Intuitive Surgical, Inc. faces various internal and external risks that could impact its financial health. Key risks include:
- Industry Competition: The company operates in a highly competitive industry with several companies developing robotic-assisted surgical systems. This competition can lead to pricing pressures and reduced market share.
- Regulatory Changes: Changes in healthcare regulations or reimbursement policies could adversely affect the company’s business model and profitability.
- Market Conditions: Economic fluctuations can impact hospital budgets and spending on capital equipment, which may reduce demand for surgical systems.
Operational Risks
Operational risks include:
- Supply Chain Disruptions: The company relies on a global supply chain for components. Disruptions could lead to delays in production and product availability.
- Product Launch Risks: The introduction of new products, such as the da Vinci 5 surgical system, involves risks related to customer acceptance and operational readiness.
Financial Risks
Financial risks highlighted in recent earnings reports include:
- Foreign Currency Risk: Approximately 24% of revenue is generated in foreign currencies, which exposes the company to fluctuations in exchange rates. For instance, foreign currency fluctuations had an unfavorable impact of $2 million on OUS total revenue for the three months ended September 30, 2024.
- Debt Levels: As of September 30, 2024, total liabilities were approximately $2.16 billion, which could impact financial flexibility.
Strategic Risks
Strategic risks include:
- Market Penetration: The company has a significant reliance on the U.S. market, which accounted for 68% of total revenue for the three months ended September 30, 2024. This reliance poses risks if U.S. market dynamics change.
- Innovation Risks: The need for continuous innovation in surgical technologies is critical. Failure to innovate could lead to a loss of competitive advantage.
Mitigation Strategies
The company has implemented various strategies to mitigate these risks:
- Diverse Product Portfolio: By expanding its product offerings, including the Ion system, the company aims to reduce reliance on a single product line.
- Global Expansion: Investments in international markets are intended to diversify revenue sources and reduce dependence on the U.S. market.
| Risk Type | Description | Impact |
|---|---|---|
| Operational | Supply Chain Disruptions | Delays in production and product availability |
| Financial | Foreign Currency Risk | Unfavorable exchange rate fluctuations affecting revenue |
| Strategic | Market Penetration | High reliance on U.S. market may expose to volatility |
| Regulatory | Healthcare Policy Changes | Potential adverse effects on business model and profitability |
Future Growth Prospects for Intuitive Surgical, Inc. (ISRG)
Future Growth Prospects for Intuitive Surgical, Inc.
Key Growth Drivers
Product Innovations: The launch of the da Vinci 5 surgical system is expected to enhance procedure capabilities. During the nine months ended September 30, 2024, a total of 1,033 da Vinci surgical systems were placed, representing an increase of 78 units compared to 955 units for the same period in 2023 .
Market Expansion: The company continues to penetrate international markets, with 220 systems placed in Europe and 225 in Asia during the nine months ended September 30, 2024 . This is indicative of a growing global demand for robotic-assisted surgical systems, particularly in regions like Japan and India .
Future Revenue Growth Projections and Earnings Estimates
Total revenue is projected to increase by 17% to $2.04 billion for the three months ended September 30, 2024, compared to $1.74 billion for the same period in 2023. Additionally, for the nine months ended September 30, 2024, total revenue increased by 14% to $5.94 billion, up from $5.20 billion. Analysts estimate continued growth, with expectations for annual revenue exceeding $8 billion by 2025 .
| Metric | 2023 | 2024 (Projected) |
|---|---|---|
| Total Revenue | $5.20 billion | $5.94 billion |
| Revenue Growth Rate | 14% | 17% |
| Net Income | $1.19 billion | $1.64 billion |
Strategic Initiatives and Partnerships
Strategic partnerships with healthcare providers and technology companies are anticipated to drive innovation and expand market access. The company has increased capital expenditures to support R&D initiatives, with R&D expenses reaching $286 million for the three months ended September 30, 2024, compared to $249 million in the previous year.
Competitive Advantages
The company holds a competitive edge due to its established brand reputation in robotic-assisted surgery and a growing installed base of approximately 9,539 da Vinci systems as of September 30, 2024, a 15% increase from 8,285 systems in the prior year . The installed base not only contributes to recurring revenue but also enhances customer loyalty and operational efficiency.
Furthermore, the company reported approximately 670,000 da Vinci procedures performed in Q3 2024, a 18% increase from 567,000 in Q3 2023, indicating robust demand for its surgical systems. This growing utilization of existing systems reinforces the potential for future revenue growth through increased procedure volumes.
Summary of Key Growth Metrics
| Metric | Q3 2023 | Q3 2024 |
|---|---|---|
| Da Vinci Procedures | 567,000 | 670,000 |
| Ion Procedures | 14,500 | 25,000 |
| Installed Base | 8,285 systems | 9,539 systems |
Intuitive Surgical, Inc. (ISRG) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Intuitive Surgical, Inc. (ISRG) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Intuitive Surgical, Inc. (ISRG)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Intuitive Surgical, Inc. (ISRG)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.